2021
Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study
Gutierrez JI, Dubov A, Altice FL, Vlahov D. Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Medical Research 2021, 8: 32. PMID: 34006328, PMCID: PMC8132436, DOI: 10.1186/s40779-021-00323-6.Peer-Reviewed Original ResearchConceptsDaily tabletHuman immunodeficiency virus (HIV) infectionMilitary healthcare settingsImmunodeficiency virus infectionPre-exposure prophylaxisU.S. military menTelehealth visitsResultsA totalVirus infectionProvider typeUtility scoresPrEP programHealthcare settingsMental healthMilitary providersProphylaxisMenSexInjectionConjoint analysis studyMilitary menService deliverySocial media groupsMedia groupsMedications
2020
A qualitative study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction
Meyer JP, Culbert GJ, Azbel L, Bachireddy C, Kurmanalieva A, Rhodes T, Altice FL. A qualitative study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction. Harm Reduction Journal 2020, 17: 86. PMID: 33129341, PMCID: PMC7603760, DOI: 10.1186/s12954-020-00435-7.Peer-Reviewed Original ResearchConceptsNeedle/syringe programsMethadone maintenance therapyHIV prevention effortsMental health consequencesDiphenhydramine injectionMaintenance therapyOpioid dependenceHIV transmissionState of euphoriaSyringe programsIllicit injectionSkin infectionsMethadone utilizationStudy participantsHarmful drugsHealth consequencesMethadonePrevention effortsHarm reductionAntihistaminesInjectionFurther investigationKyrgyz prisonsVisible woundsQualitative study
2019
HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy
LaMonaca K, Dumchev K, Dvoriak S, Azbel L, Morozova O, Altice FL. HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy. Current Psychiatry Reports 2019, 21: 47. PMID: 31161306, PMCID: PMC6685549, DOI: 10.1007/s11920-019-1038-8.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programDrug injectionAntiretroviral therapyHIV epidemicEvidence-based HIV prevention strategiesNew HIV casesHIV prevention strategiesHarm reduction programsAgonist therapyHIV incidenceHIV casesRecent FindingsThoughPrevention strategiesSexual partnersHIVInjectionTherapyReduction programsEpidemicPunitive drug lawsService programsMortalityCliniciansIncidence
2018
Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments
Azbel L, Wegman MP, Polonsky M, Bachireddy C, Meyer J, Shumskaya N, Kurmanalieva A, Dvoryak S, Altice FL. Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments. International Journal Of Prisoner Health 2018, 14: 175-187. PMID: 30274558, PMCID: PMC6447033, DOI: 10.1108/ijph-03-2017-0016.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentNeedle syringe programsDrug injectionDrug injectorsHigh HIV risk behaviorElevated HIV riskPrison drug injectionHepatitis C infectionOpioid agonist treatmentHIV risk behaviorsC infectionHIV incidenceAgonist treatmentMaintenance treatmentIndependent correlatesBiobehavioral surveysHIV riskOnly examinationRisk behaviorsMMT useLow uptakeCurrent incarcerationInjectionLogit linkHigh-risk environmentsExtended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppression
2009
Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal Of Drug And Alcohol Abuse 2009, 35: 68-72. PMID: 19212931, PMCID: PMC2791788, DOI: 10.1080/00952990802585406.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid withdrawal symptomsSyringe sharingWithdrawal symptomsSnowball recruitment techniquesLogistic regression analysisDiversion of buprenorphineLack of reductionEvidence-based approachPrimary outcomeBuprenorphine injectionOnly symptomBenzodiazepine useBenzodiazepine injectionStomach painBuprenorphineInjection doseRisk behaviorsSymptomsNaloxoneInjectionRegression analysisNLXDaily amountDose
2008
Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia
Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. The American Journal Of Drug And Alcohol Abuse 2008, 34: 511-517. PMID: 18584580, DOI: 10.1080/00952990802122259.Peer-Reviewed Original ResearchConceptsBuprenorphine injectionBuprenorphine injectorsCase seriesSignificant adverse health consequencesProspective cohort studyPossible pharmacological interactionsAdverse health consequencesDiversion of buprenorphineCohort studyResultant symptomsPoor outcomeCase reportTreatment modalitiesPharmacological interactionsBuprenorphineEuphoric effectsHealth consequencesKuala LumpurMidazolamInjectionQualitative interviewsSymptoms